A highly contractile phenotype is clearly critical for effective cancer colonization, ultimately supporting the idea of developing drugs to inhibit actomyosin contractility.In vivo validation of the role of Rho/ROCK signaling or actomyosin contractility (or both) in metastasis is important to qualify these signaling modules as potential drug targets. Here, RHO is linked to cancer.